Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Trial Identifier:	D8220C00036
Sponsor:	AstraZeneca
Collaborator:	AbbVie Inc Genentech, Inc
Start Date:	September 2025
Primary Completion Date:	November 2032
Study Completion Date:	November 2032
Condition:	CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.